Hyperpigmentation and age spot treatments have been a bonanza for skincare marketers. Erasing years of aging, sun damage and hormonal damage is the kind of visible benefit that consumers crave. More so than wrinkles, it is discoloration and unevenness that humans focus on to judge youth and status. Tranexamate technology has emerged as a next generation approach. It not only prevents age spots, it addresses the inflammation and unevenness that occurs prior to age spot formation — with incredible impact even on younger users. Actera will introduce TXVector™, the first available lipophillic tranexamate, and provide detailed data on its performance in robust human clinical studies.